Trial Profile
A randomized, open label, Phase IIB trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated with Docetaxel (OSTRICh trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms OSTRICh trial
- 24 Oct 2023 Final results presented at the 48th European Society for Medical Oncology Congress
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Primary endpoint of clinical benefit rate has been met, according to results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.